A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis

Trial Profile

A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Mercaptamine bitartrate (Primary)
  • Indications Cystinosis
  • Focus Therapeutic Use
  • Sponsors Raptor Pharmaceutical Inc
  • Most Recent Events

    • 26 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 14 Jul 2017 Results published in the Horizon Pharma plc media release.
    • 14 Jul 2017 According to a Horizon Pharma plc media release, the company presented result of Halitosis Substudy (n=20) at the Cystinosis Research Network (CRN) 2017 Family Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top